Application 207495
- Type
- ANDA
- Sponsor
- AMNEAL PHARMS
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | IMATINIB MESYLATE | IMATINIB MESYLATE | TABLET;ORAL | EQ 100MG BASE | No | No |
| 002 | IMATINIB MESYLATE | IMATINIB MESYLATE | TABLET;ORAL | EQ 400MG BASE | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A207495-001 | IMATINIB MESYLATE | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | ||
| A207495-002 | IMATINIB MESYLATE | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 74a2ff9319b5… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | bb7c543d1eb4… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 782e0a99824c… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 87673890dc5c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 5aa47cf7b7d7… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 8869cabd3fbd… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | c0c555d07b60… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 3f01610625f2… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | b00525d2431f… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | AB | 2019-02-08 | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | AB | 2019-02-08 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 6a51e52b5d6a… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 1c564ffb4f44… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | ea1830bbd6c7… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | a72a2bbeb626… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 9b2671bbb829… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | a67488948f0b… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 3f0d92c62455… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 053a50430f4f… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 3bdfa0b2c4d7… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A207495-001 | IMATINIB MESYLATE | EQ 100MG BASE | TABLET / ORAL | 2019-02-08 | 3a93d1ddd44b… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A207495-002 | IMATINIB MESYLATE | EQ 400MG BASE | TABLET / ORAL | 2019-02-08 | 3a93d1ddd44b… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2019-07-19 19:46 UTC | 2019-07 | A207495-001 | AB | 1 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | A207495-002 | AB | 1 | ea99ee380514… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Imatinib Mesylate | IMATINIB MESYLATE | Apotex Corp | 0291eca5-7a1d-4a79-30be-252224d96509 | 2026-09-08 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB MESYLATE | QUALLENT PHARMACEUTICALS HEALTH LLC | a819a954-41c9-4d49-a74e-c8c4b338b22a | 2026-08-27 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB MESYLATE | Major Pharmaceuticals | 7c037022-7fc8-4b6e-9db3-427206c572b4 | 2026-08-04 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB MESYLATE | Aurobindo Pharma Limited | a4e409f7-20b4-4c80-8a6a-f95995ffad78 | 2026-07-28 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB | Mylan Pharmaceuticals Inc. | a1787fad-3612-43e1-98fa-ce62361e0b3c | 2026-07-15 | Warnings, Adverse reactions | Imatinib Mesylate |
| Gleevec | IMATINIB MESYLATE | Novartis Pharmaceuticals Corporation | 211ef2da-2868-4a77-8055-1cb2cd78e24b | 2026-07-13 | Warnings, Adverse reactions | IMATINIB MESYLATE |
| IMATINIB MESYLATE | IMATINIB MESYLATE | Civica Script LLC | 9fc5ec7b-98c4-4b1a-890c-be1343177dbd | 2026-07-03 | Warnings, Adverse reactions | IMATINIB MESYLATE IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB | Golden State Medical Supply, Inc. | 9131b2ce-752d-3a30-e053-2a95a90adaab | 2026-06-16 | Warnings, Adverse reactions | Imatinib Mesylate |
| imatinib mesylate | IMATINIB MESYLATE | Sun Pharmaceutical Industries, Inc. | 07764bf9-21b4-4e32-9d7e-e348f8e4291f | 2026-06-01 | Warnings, Adverse reactions | imatinib mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB | Safecor Health, LLC | f4acacbd-13f8-4a46-b615-b639a17f331f | 2026-04-17 | Warnings, Adverse reactions | Imatinib Mesylate |
| imatinib mesylate | IMATINIB MESYLATE | Upsher-Smith Laboratories, LLC | 5d07ac08-962e-41a8-8a3c-50febc8c5f34 | 2026-01-09 | Warnings, Adverse reactions | imatinib mesylate IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB MESYLATE | Chartwell RX, LLC | 65b4d8a6-349d-4fb1-9818-dad6b4ad4fa1 | 2025-12-10 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| IMATINIB MESYLATE | IMATINIB MESYLATE | Camber Pharmaceuticals, Inc. | e97f0238-b9da-46af-83a3-0826e39893e8 | 2025-11-25 | Warnings, Adverse reactions | IMATINIB MESYLATE IMATINIB MESYLATE |
| Imatinib Mesylate | IMATINIB | Mylan Institutional Inc | 1debf3a0-7587-47d7-8ea6-e739698d7297 | 2025-09-15 | Warnings, Adverse reactions | Imatinib Mesylate |
| Imatinib Mesylate | IMATINIB MESYLATE | American Health Packaging | 6e7ed4ef-24e3-4545-9a99-2e34c946e8e7 | 2025-02-19 | Warnings, Adverse reactions | Imatinib Mesylate IMATINIB MESYLATE |
| imatinib mesylate | IMATINIB MESYLATE | Qilu Pharmaceutical Co., Ltd. | 82eb01e0-8685-4f06-8a72-7663e8ded38f | 2024-12-04 | Warnings, Adverse reactions | imatinib mesylate IMATINIB MESYLATE |
| imatinib mesylate | IMATINIB MESYLATE | BluePoint Laboratories | be5b9047-155b-59ca-e053-2995a90ad3dc | 2023-09-21 | Warnings, Adverse reactions | imatinib mesylate IMATINIB MESYLATE |
| imatinib mesylate | IMATINIB MESYLATE | Archis Pharma LLC | 9de8d8b9-cf88-4960-82b7-89e5ceb7720e | 2023-09-21 | Warnings, Adverse reactions | imatinib mesylate IMATINIB MESYLATE |
| Imatinib mesylate 400 mg | IMATINIB MESYLATE | Armas Pharmaceuticals Inc. | 7b7cc194-29e4-4484-a364-a1ac7d7d6cf5 | 2019-03-08 | Warnings, Adverse reactions | IMATINIB MESYLATE |
| Imatinib mesylate | IMATINIB MESYLATE | Armas Pharmaceuticals Inc. | 2e931c49-6c9f-41e2-a34b-5f01cd295b56 | 2019-03-04 | Warnings, Adverse reactions | Imatinib mesylate IMATINIB MESYLATE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 65162-794 | Imatinib Mesylate | Imatinib | Amneal Pharmaceuticals LLC | ANDA | Current |
| 65162-794 | Imatinib Mesylate | Imatinib | Amneal Pharmaceuticals LLC | ANDA | Current |
| 65162-794 | Imatinib Mesylate | Imatinib | Amneal Pharmaceuticals LLC | ANDA | Current |
| 65162-795 | Imatinib Mesylate | Imatinib | Amneal Pharmaceuticals LLC | ANDA | Current |
| 65162-795 | Imatinib Mesylate | Imatinib | Amneal Pharmaceuticals LLC | ANDA | Current |
| 65162-795 | Imatinib Mesylate | Imatinib | Amneal Pharmaceuticals LLC | ANDA | Current |